Comparison of clinical outcome of fixed-dose subcutaneous low molecular weight heparin (Tinzaparin) with conventional heparin in unstable angina: A pilot study

Indian Heart Journal

Volumn 49, Issue 2, 1997, Pages 159-162

  Suvarna, T T ^a   Parikh, J A ^a,b   Keshav, R ^a   Pillai, M G ^a   Pahlajani, D B ^a   Gandhi, M J ^a  

^a Nanavati Hospital ^*  (India)

^b NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ADULT; ANGIOGRAPHY; ANGIOPLASTY; ARTICLE; BLEEDING; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PATIENT MONITORING; RISK FACTOR; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PILOT PROJECTS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 0030825510     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988; 77: 1213-1220
2. Davies MJ, Thomas A. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death and crescendo angina. Br Heart J 1985; 53: 363-373
3. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985; 313: 1369-1375
4. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat unstable angina. N Engl J Med 1988; 319: 1105-1111
5. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-830
6. Theroux P, Waters D, Qui S, et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88: 2045-2048
7. Maraganore JM, Bourdon P, Adelman B, Cannon CP, Theroux P. Heparin variability and resistance: comparisons with a direct thrombin inhibitor. Circulation 1992; 86(suppl I): I-386
8. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574
9. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17
10. Salzman EW. Low molecular weight heparin. Is small beaufiful? N Engl J Med 1986; 315: 957-959
11. Melandri G, Semprini F, Cervi V. Comparison of efficacy of low molecular weight heparin to unfractionated heparin in presence of activated platelets in healthy subjects. Am J Cardiol 1993; 72: 450-454
12. Lewis DH, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983; 309: 396-403
13. Tedford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981; 1: 1225-1228
14. Neri Serneri GG, Gensini GF, Pogessi L, et al. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischemia in refractory unstable angina. Lancet. 1990; 335: 615-618
15. Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina following discontinuation of heparin. N Engl J Med 1992; 327: 141-145
16. Becker RC, Corrao JM, Ball SP, Gore JM. A comparison of heparin strategies after thrombolytic therapy. Am Heart J 1993; 126: 750-752
17. Theroux P, Lidon R. Anticoagulants and their use in acute ischemic syndromes. In: Topol's Textbook of Interventional Cardiology. WB Saunders Co. 1994
18. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995; 26: 313-318
19. FRISC Study Group. Low-molecular weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-568
20. Sobel M, McNeill PM, Carlson PL, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991; 87: 1787-1793